IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors.
| Author | |
|---|---|
| Abstract |
:
Somatic mutations in IDH1/2 occur in ~20% of patients with myeloid neoplasms, including acute myeloid leukemia (AML). IDH1/2MUT enzymes produce D-2-hydroxyglutarate (D2HG), which associates with increases in DNA damage and improved responses to chemo/radiotherapy and PARP inhibitors in solid tumor cells. Whether this also holds true for IDH1/2MUT AML is not known. |
| Year of Publication |
:
2018
|
| Journal |
:
Clinical cancer research : an official journal of the American Association for Cancer Research
|
| Date Published |
:
2018
|
| ISSN Number |
:
1078-0432
|
| URL |
:
http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=29339439
|
| DOI |
:
10.1158/1078-0432.CCR-17-2796
|
| Short Title |
:
Clin Cancer Res
|
| Download citation |
